PURE Bioscience, Inc. (OTCQB: PURE) announced that Jeff Kitchell will assume the role of President, in addition to his duties as Corporate Secretary, effective November 17, 2025. In parallel, Dolana Blount was promoted to Vice President of Operations while retaining her responsibilities as Vice President of Regulatory Affairs, also effective November 17, 2025.
Jeff Kitchell brings 24 years of experience at PURE, most recently serving as Vice President of Operations. His promotion to President signals the company’s intent to separate the CEO and President functions, allowing CEO Robert Bartlett to focus exclusively on strategic leadership while Kitchell drives operational execution and strategic development across the organization.
Dolana Blount, who has spent 27 years with PURE, has been a key figure in intellectual property and product development. By adding operational responsibilities to her portfolio, PURE is reinforcing its focus on efficient execution and regulatory compliance, two pillars critical to the company’s growth in the antimicrobial market.
The restructuring reflects PURE’s broader strategy to expand its product portfolio and market reach. Separating the CEO and President roles is intended to sharpen focus on day‑to‑day operations and long‑term strategy, a move that aligns with the company’s commitment to internal talent development and institutional knowledge.
PURE Bioscience specializes in proprietary antimicrobial products for the food and beverage industry, leveraging its patented Silver Dihydrogen Citrate (SDC) technology. The leadership changes are positioned to support the company’s ongoing transformation and to accelerate the commercialization of new products in a competitive market.
Management views the appointments as a sign of stability and confidence in the company’s internal talent pipeline. By promoting long‑tenured executives, PURE signals that it values continuity and deep industry expertise as it navigates growth opportunities and operational challenges.
CEO Robert Bartlett said, "These leadership appointments reinforce PURE’s commitment to fostering strong internal talent." Bartlett added that the new structure will allow him to devote more attention to his CEO responsibilities while Kitchell and Blount lead the company’s operational and strategic initiatives.
The appointments are part of a broader transformation effort aimed at strengthening executive leadership, enhancing operational efficiency, and positioning PURE for continued growth in the antimicrobial sector.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.